Powered by 
Technavio
Foundation Medicine Inc. | Data-Driven Analysis and Industry Review
Published: August 21, 2024Foundation Medicine Inc. is a leading precision medicine company that aims to revolutionize the diagnosis, treatment, and monitoring of cancer through its comprehensive genomic profiling services. The company provides physicians and their patients with deep insights into the molecular drivers of cancer, enabling informed treatment decisions. Foundation Medicine's test, FoundationOne CDx, analyzes over 300,000 genetic variants in a single test, providing a comprehensive understanding of a patient's tumor and arming healthcare providers with essential information to make effective treatment plans. With a commitment to advancing personalized medicine, Foundation Medicine is dedicated to improving lives by providing critical information to physicians at the right place and right time.'
1. Leading provider of comprehensive genomic profiling (CGP) services for personalized cancer treatment: Foundation Medicine offers sophisticated genomic analysis of solid tumors and hematological malignancies to identify actionable mutations and potential treatment options for patients.
2. Broad molecular insights: The company's CGP tests cover over 400 genes and select signaling pathways, providing comprehensive molecular information to inform treatment decisions and facilitate clinical trials.
3. Collaborative partnerships: Foundation Medicine collaborates with major pharmaceutical companies, academic institutions, and healthcare organizations to expand the understanding of genomic data and improve patient care.
4. Integration with electronic health records (EHRs) and clinical workflows: Foundation Medicine's tests are designed to seamlessly integrate with EHRs and clinical workflows, enabling efficient and effective use of genomic data in the clinical setting.
5. Continuous innovation: The company invests in research and development to expand its test offerings and improve its analytical capabilities, ensuring that it remains at the forefront of personalized cancer care.
1. Foundation Medicine utilizes comprehensive genomic profiling to identify genetic alterations in a patient's tumor, providing critical information for precision cancer treatment.
2. Their proprietary technology, FoundationOne, analyzes over 300,000 genetic variants across the entire genome and transcriptome, including single nucleotide variants, copy number alterations, and fusion genes.
3. The company's data-driven insights enable oncologists to make informed treatment decisions, including identifying targeted therapies and clinical trials, and monitoring response to therapy.
4. Foundation Medicine's real-time data analytics platform, FoundationOneLiquid, offers rapid turnaround time for results, allowing for personalized treatment plans in a timely manner.
5. The company collaborates with major pharmaceutical companies, academic institutions, and other organizations to expand the understanding of genomic data in cancer treatment and improve patient outcomes.
Browse Our Research Portfolio In Foundation Medicine Inc. Markets
Health Care
Biotechnology and Life Sciences
Biotechnology
Pharmaceuticals
About Technavio
With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.
